JP2021525225A - 掻痒症を治療するための組成物及び方法 - Google Patents

掻痒症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2021525225A
JP2021525225A JP2020551516A JP2020551516A JP2021525225A JP 2021525225 A JP2021525225 A JP 2021525225A JP 2020551516 A JP2020551516 A JP 2020551516A JP 2020551516 A JP2020551516 A JP 2020551516A JP 2021525225 A JP2021525225 A JP 2021525225A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sde
acid
pruritus
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525225A5 (enExample
Inventor
チャーン，ウェンディ，フアン
リー，チャン−ジュン
クオ，シュー−ウェン
チョウ，デイビット，チー−クアン
ティエン，ユ−エン
Original Assignee
ルモサ セラピューティクス カンパニー， リミテッド
ルモサ セラピューティクス カンパニー， リミテッド
シャンハイ ルーモサ セラピューティクス カンパニー リミテッド
シャンハイ ルーモサ セラピューティクス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルモサ セラピューティクス カンパニー， リミテッド, ルモサ セラピューティクス カンパニー， リミテッド, シャンハイ ルーモサ セラピューティクス カンパニー リミテッド, シャンハイ ルーモサ セラピューティクス カンパニー リミテッド filed Critical ルモサ セラピューティクス カンパニー， リミテッド
Publication of JP2021525225A publication Critical patent/JP2021525225A/ja
Publication of JP2021525225A5 publication Critical patent/JP2021525225A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020551516A 2018-03-29 2019-03-28 掻痒症を治療するための組成物及び方法 Pending JP2021525225A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650108P 2018-03-29 2018-03-29
US62/650,108 2018-03-29
PCT/US2019/024706 WO2019191511A1 (en) 2018-03-29 2019-03-28 Compositions and methods for treating pruritus

Publications (2)

Publication Number Publication Date
JP2021525225A true JP2021525225A (ja) 2021-09-24
JP2021525225A5 JP2021525225A5 (enExample) 2022-04-11

Family

ID=68054657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551516A Pending JP2021525225A (ja) 2018-03-29 2019-03-28 掻痒症を治療するための組成物及び方法

Country Status (13)

Country Link
US (2) US20190298702A1 (enExample)
EP (1) EP3755328A4 (enExample)
JP (1) JP2021525225A (enExample)
KR (1) KR20200138730A (enExample)
CN (1) CN112040948A (enExample)
AU (1) AU2019243571A1 (enExample)
BR (1) BR112020019094A2 (enExample)
CA (1) CA3094710A1 (enExample)
IL (1) IL277463A (enExample)
MX (1) MX2020009813A (enExample)
RU (1) RU2020130919A (enExample)
TW (1) TWI729371B (enExample)
WO (1) WO2019191511A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121401263A (zh) * 2020-02-14 2026-01-27 帝国制药美国公司 外用纳洛酮组合物及其使用方法
CN113797167B (zh) * 2020-06-16 2024-05-10 苏州恩华生物医药科技有限公司 一种塞纳布啡的储库制剂
IL298929A (en) * 2020-06-30 2023-02-01 Dermira Inc IRAK4 inhibitors and their topical uses
WO2022175973A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
JP2013521232A (ja) * 2010-02-26 2013-06-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
JP2015500292A (ja) * 2011-12-08 2015-01-05 ライジェル ファーマシューティカルズ， インコーポレイテッド 化合物を投与するための局所用製剤
JP2017517553A (ja) * 2014-06-13 2017-06-29 トレビ セラピューティクス インコーポレイテッド 掻痒の治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130759C (enExample) * 1965-10-07
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
ES2188481T3 (es) * 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
US20140112957A1 (en) * 2012-10-19 2014-04-24 Oliver Yao-Pu Hu Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form
JP6935393B2 (ja) * 2015-05-28 2021-09-15 ルモサ セラピューティクス カンパニー， リミテッド セバコイルジナルブフィンエステルの徐放のための医薬製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
JP2013521232A (ja) * 2010-02-26 2013-06-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
JP2015500292A (ja) * 2011-12-08 2015-01-05 ライジェル ファーマシューティカルズ， インコーポレイテッド 化合物を投与するための局所用製剤
JP2017517553A (ja) * 2014-06-13 2017-06-29 トレビ セラピューティクス インコーポレイテッド 掻痒の治療方法

Also Published As

Publication number Publication date
AU2019243571A1 (en) 2020-10-15
EP3755328A4 (en) 2021-11-10
EP3755328A1 (en) 2020-12-30
TW202002977A (zh) 2020-01-16
RU2020130919A3 (enExample) 2022-04-29
CN112040948A (zh) 2020-12-04
CA3094710A1 (en) 2019-10-03
TWI729371B (zh) 2021-06-01
US20190298702A1 (en) 2019-10-03
RU2020130919A (ru) 2022-04-29
KR20200138730A (ko) 2020-12-10
BR112020019094A2 (pt) 2020-12-29
MX2020009813A (es) 2020-11-11
WO2019191511A1 (en) 2019-10-03
US20220362226A1 (en) 2022-11-17
IL277463A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US20220362226A1 (en) Compositions and methods for treating pruritus
US20250049817A1 (en) Jak inhibitor with a vitamin d analog for treatment of skin diseases
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
EP4091612B1 (en) Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
DK2640370T3 (en) COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE RESOURCES
US20200261427A1 (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
JP2021014469A (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
KR20230004644A (ko) 약제학적 조성물
AU2017247963A1 (en) Topical composition comprising tacrolimus
KR20230122024A (ko) 타피나로프의 겔, 연고, 및 폼 제형 및 사용 방법
KR20230054682A (ko) Jak 저해제 및 라우레스-4를 함유하는 국소 제형
US20220249470A1 (en) Treatment of skin disorders by topical administration of vegf inhibitors
AU2022202941A1 (en) Stable topical compositions of fenoldopam
EP2554184B1 (en) Preventive and/or remedy for hand and foot syndrome
HK40036943A (en) Compositions and methods for treating pruritus
EP4719595A1 (en) (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1h-pyrazole-1-carboximidamide hydrochloride and dermal formulations thereof
WO2025068281A1 (en) CORTEXOLONE-17α-PROPIONATE FOR TREATING ACNEIFORM ERUPTIONS
EP4529925A1 (en) Cortexolone-17-alpha- propionate for treating acneiform eruptions
EP4467159A1 (en) (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1hpyrazole- 1-carboximidamide hydrochloride and dermal formulations thereof
KR20000066357A (ko) 케토롤락 외용제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230809